Document Type: Original Article
Authors
1 Microbiology Department, Pasteur Institute of Iran, Tehran, Iran
2 Virology Department, Pasteur Institute of Iran, Tehran, Iran
3 Biochemistry Department, Pasteur Institute of Iran, Tehran, Iran
4 Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran
Keywords
Anmol Kumar AK, KK Pulicherla KKP, K. Seetha Ram KSR, KRS Sam
basiva Rao KRSSR. Evolutionary trend of thrombolytics. Int J Bio Sci Bio Technol 2010; 2:51-68.
2. Banerjee A, Chisti Y, Banerjee UC. Streptokinase--a clinically useful thrombolytic agent. Biotechnol Adv 2004; 22:287-307.
3. Kunamneni A, Abdelghani TTA, Ellaiah P. Streptokinase—the drug of choice for thrombolytic therapy. J Thromb Thrombolysis. 2007; 23:9-23.
4. Baruah DB, Dash RN, Chaudhari M, Kadam S. Plasminogen activators: A comparison. Vasc Pharmacol 2006; 44:1-9.
5. Della G, Miocardico SNI. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336:65-71.
6. Ridker PM, O’Donnell C, Marder VJ, Hennekens CH. Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Int Med 1993; 119:530.
7. Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Texas Heart Institute J 2007; 34:318-327.
8. Abdelghani TTA, Kunamneni A, Ellaiah P. Isolation and mutagenesis of streptokinase producing bacteria. Am J Immunol 2005; 1:125-129.
9. Arabi R, Roohvand F, Noruzian D, sardari S, Aghasadeghi MR, Khanamad H,
et al
. A comparative study on the activity and antigenicity of truncated and full-length forms of streptokinase. Polish J Microbiol 2011; 60:243-252.
10. Malke H. Polymorphism of the streptokinase gene: implications for the pathogenesis of post-streptococcal glomerulonephritis. Zentralblatt für Bakteriologie. Int J Med Microbiol 1993; 278:246- 253.
11. Malke H, Steiner K, Gase K, Mechold U, Ellinger T. The streptokinase gene: allelic variation, genomic environment and expression control. Dev Biol Stand 1995; 85:183.
12. Pupo E, Baghbaderani BA, Lugo V, Fernández J, Páez R, Torréns I. Two streptokinase genes are expressed with different solubility in Escherichia coli W3110. Biotechnol lett 1999; 21:1119-1123.
13. Keramati M, Roohvand F, Eslaminejad Z, Nikbin VS, Aslani MM. PCR/RFLP-based allelic variants of streptokinase and their plasminogen activation potencies. FEMS Microbiol Lett 2012; 335:79- 85.
14. Tewodros W, Norgren M, Kronvall G. Streptokinase activity among group A streptococci in relation to streptokinase genotype, plasminogen binding, and disease manifestations. Microbial Pathogenesis 1995; 18:53-65.
15. Al Sohaimy S, Aleem E, Hafez EE, Esmail SS, El-Saadani M, Moneim NA. Expression of recombinant Streptokinase from local Egyptian Streptococcus sp. SalMarEg. Afr J Biotechnol 2011; 105:9001- 9011.
16. Freeda F. Production and partial purification of streptokinase by streptococcus sp. Int J Students Project (IJSP)-Biotechnol 2010; 1:1-39.
17. Doss HM, Manohar M, Singh NA, Mohanasrinivasan V, Devi CS. Studies on isolation, screening and strain improvement of streptokinase producing -hemolytic streptococci. World J Sci Technol 2011; 1:7-11.
18. Garrity GM, Brenner DJ, Krieg NR. Bergey’s manual of systematic bacteriology. Springer; 2005.
19. Kim DM, Lee SJ, Kim IC, Kim ST, Byun SM. Asp41-His48 region of streptokinase is important in binding to a substrate plasminogen. Thrombosis Res 2000; 99:93-98.
20. Sambrook J, Russell DW. The condensed protocols from molecular cloning: a laboratory manual: Cold Spring Harbor Laboratory
619
Pr; 2006; 8.
21. Crowe J, Henco K. The QIAexpressionist. DIAGEN GmbH, Hilden, Germany: 1992.p.2.
22. Ingham KC. Precipitation of proteins with polyethylene glycol. Methods Enzymol 1990; 182:301-306.
23. Wohl RC, Summaria L, Robbins K. Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37 degrees C. J Biologic Chem 1980; 255:2005-2011.
24. Wu XC, Ye R, Duan Y, Wong SL. Engineering of plasmin-resistant forms of streptokinase and their production in Bacillus subtilis: streptokinase with longer functional half-life. App Environ Mi�crobiol 1998; 64:824-830.
25. Pimienta E, Ayala JC, Rodríguez C, Ramos A, Van Mellaert L, Vallín C,
et al
. Recombinant production of Streptococcus equisimilis streptokinase by Streptomyces lividans. Microb Cell Fact 2007; 6:20-31.
26. Sands D, Whitton C, Longstaff C. International collaborative study to establish the 3rd International Standard for Streptokinase. J Thromb Haemost 2004; 2:1411-1415.
27. Winn WC, Koneman EW. Koneman’s color atlas and textbook of diagnostic microbiology. Lippincott williams & wilkins; 2006.
28. Hughes JM, Wilson ME, Brandt CM, Spellerberg B. Human infections due to Streptococcus dysgalactiae subspecies equisimilis. Clin Infect Dis 2009; 49:766-772.
29. Barnham M, Kerby J, Chandler R, Millar M. Group C streptococci in human infection: a study of 308 isolates with clinical correlations. Epidemiol Infect 1989; 102:379-390.
30. Davies MR, McMillan DJ, Sriprakash KS, Chhatwal GS. Distribution of group A streptococcal virulence genes in group C and G streptococci. Int Cong Series 2006; 1289:184-187.
31. Steiner K, Malke H. Dual control of streptokinase and streptolysin S production by the covRS and fasCAX two-component regulators in Streptococcus dysgalactiae subsp. equisimilis. InfectImmun. 2002; 70:3627-3636.
32. Kim MR, Choeng YH, Chi WJ, Kang DK, Hong SK. Heterologous production of streptokinase in secretory form in streptomyces lividans and in nonsecretory form in escherichia coli. J Microbiol Biotechnol 2010; 20:132-137.
33. Balagurunathan B, Ramchandra NS, Jayaraman G. Enhancement of stability of recombinant streptokinase by intracellular expression and single step purification by hydrophobic interaction chromatography. Biochem Engineering Journal. 2008;39(1):84- 90.
)